+44 (0) 141 202 2888

Symposia

BSH are delighted to have the support of incredible companies hosting 13 Satellite Symposia. Covering a range of subjects, they complement the main programme.

 

 

Monday 27 March - 16:30 - 17:45

Boehringer Ingelheim

Syndicate Room 1

Mythbusting: exposing the facts for Non-Vitamin K Antagonist Oral Anticoagulants in Non-Valvular Atrial Fibrillation

Dr Keeling

Dr Alikhan

Dr Kelvin Lee




Celgene

Syndicate Room 2

AML (Acute Myeloid Leukaemia) at a Crossroads. Is Targeted or Immunotherapy the Way to Go?

Prof Mhairi Copland, Gartnavel General Hospital, Glasgow

Prof Mary Frances McMullin, Belfast City Hospital, Belfast

Prof Jamie Cavenagh, St. Bartholomew's Hospital, London

 

Chair: Dr Jonathan Kell, University Hospital of Wales

Janssen

Syndicate Room 3

Sequencing Treatment for Mantle Cell Lymphoma and Chronic Lymphocytic Leukaemia; Time for a Consensus? An Interactive Case Based Session

Dr Kim Linton, Christie NHS Foundation Trust, Manchester

Prof Clemens Wendtner, University of Cologne, Germany

 

Chair: Dr George Follows, Cambridge University Hospitals NHS Foundation Trust, UK

Takeda

Syndicate Room 4

Spotlight on Myeloma: The Evolving Treatment Landscape

Prof Paul Richardson, Dana-Farber Cancer Institute, Boston, MA, USA 

Dr Karthik Ramasamy, Oxford University Hospitals, Oxford

Dr Matthew Jenner, University Hospital Southampton, Southampton

 

Chair: Professor Kwee Yong, University College Hospital, London

Monday 27 March - 18:00 - 19:15

BMS

Syndicate Room 1

Looking to the future: Immunotherapy in classical Hodgkin lymphoma

Dr Frederick Arce Vargas, UCL, Institutional Research Information Service (IRIS)

Prof John Radford, The Christie NHS Foundation Trust

Dr Shankara Paneesha, Heartlands Hospital

 

Chair: Prof John Radford, The Christie NHS Foundation Trust

Celgene

Syndicate Room 2

New Perspectives on Extending Remission in Multiple Myeloma

Dr Roger Owen, St James’s Hospital, Leeds

Prof Thierry Facon, Centre Hospitalier Régional Universitaire de Lille, France

Dr Neil Rabin, University College Hospital, London

 

Chair: Dr Mark Cook, Queen Elizabeth Hospital, Birmingham

Gilead

Syndicate Room 3

Mutational Status of the TP53 Gene - Clinical Implications for the 'High-Risk' CLL Patient

Prof Andy Pettitt, Royal Liverpool University Hospital, Liverpool

Prof Chris Fegan, University Hospital of Wales, Cardiff

Dr Sunil Iyengar, Royal Marsden, London

Dr Mark Catherwood, Belfast City Hospital, Belfast

 

Chair: Professor Anna Schuh, John Radcliffe Hospital, Oxford

Tuesday 28 March - 13:30 - 14:15

Abbvie

Plenary

The new era of BCL2 inhibition – Expert perspective on Venetoclax (VENCLYXTO®) in CLL

Prof John Gribben, Barts’ Cancer Institute, London

Prof Peter Hillmen, St. James’ University Hospital, Leeds

Dr. Claire Dearden, The Royal Marsden Hospital, London

 

Chair: Professor John Gribben, Barts’ Cancer Institute

Tuesday 28 March - 16:15 - 17:30

AddMedica

Syndicate Room 1

Sickle Cell Disease Patient Management : UK & France Practice Sharing

Prof Frédéric Galacteros, Paris

Prof David Rees, King’s College Hospital NHS Foundation Trust, London

Dr Valentine Brousse, Hôpital Necker-Enfants Malades, Paris

Prof Jo Howard, Guys & St Thomas' NHS Foundation Trust, London

 

Chairs: 

Prof Frédéric Galacteros, Paris

Prof David Rees, King’s College Hospital NHS Foundation Trust, London

 

 



Janssen

Syndicate Room 2

Closing the gap: the emerging role of immunotherapy in relapsed and/or refractory Multiple Myeloma

Prof Paul Richardson, Dana-Farber Cancer Institute, Boston, USA

Dr Matthew Streetly, Guy’s and St. Thomas’ NHS Foundation Trust, London

 

Chair: Professor Graham Jackson, Consultant Haematologist, The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne

Roche

Syndicate Room 3

Measuring Success in Indolent Disease: Discuss, Debate, Decide

Dr George Follows, Cambridge University Hospitals NHS Foundation Trust, UK

Dr Christopher Fox, Nottingham University Hospital, Nottingham

 

Chair: Dr Graham Collins, Churchill Hospital, Oxford

Napp Pharmaceuticals Limited

Syndicate Room 4

The R-Evolution. The introduction of biosimilar rituximab in Haemato-Oncology

Dr Mark Verrill,  Freeman Hospital, Newcastle

Mr Steve Williamson, Consultant Services, Northumbria Healthcare

 

Chair: Professor Chris Fegan, University Hospital of Wales, Cardiff